BTAI Delivers Over 300% In Less Than 2 Months - SERENITY At-Home Trial Data Due This Month

BioXcel Therapeutics Inc. (BTAI) has a clinical trial catalyst to watch this month, related to its lead drug, IGALMI, in an expanded indication.

from RTT - Top Story https://ift.tt/Npxh9gY
via IFTTT